Treatment News : European Health Agency Wants More Answers About PrEP

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 29, 2014

European Health Agency Wants More Answers About PrEP

The European Centre for Disease Prevention and Control (ECDC) has stated that the agency is not ready to issue a recommendation about the use of pre-exposure prophylaxis (PrEP) to prevent HIV in Europe, aidsmap reports. Its conservative approach to PrEP results from outstanding questions about efficacy, cost-effectiveness, side effects, drug resistance and whether PrEP will lead to a drop in condom use.

The ECDC has stated that the PrEP strategy “merits some mention” and “shows promising prospects for inclusion in the ‘HIV prevention toolbox’ in Europe.” Acknowledging encouraging results in recent research of Truvada (tenofovir/emtricitabine) as PrEP, the agency cites an array of outstanding questions including:

Cost-effectiveness—which is likely predicated upon high adherence rates—as well as affordability.
Whether it is justifiable to provide antiretrovirals to people who do not have HIV while not all those who are living with the virus and who need treatment have received it.
Whether PrEP will divert funds from other HIV prevention efforts.
How to determine who will be eligible, taking into consideration the high cost.
How to encourage maximum adherence.
Whether PrEP will lead to a drop in condom use and how such a shift may affect overall HIV transmission risks.

To read the aidsmap story, click here.

Search: PrEP, pre-exposure prophylaxis, European Centre for Disease Prevention and Control, ECDC, aidsmap, Truvada, tenofovir, emtricitabine.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.